Cancer Immunology, Immunotherapy

, Volume 62, Issue 10, pp 1609–1618

Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis

Authors

  • Monireh Mohsenzadegan
    • Immunology Research CentreIran University of Medical Sciences
    • Department of ImmunologyIran University of Medical Sciences
    • Department of Pathology, Oncopathology Research CentreIran University of Medical Sciences
    • Department of Molecular MedicineIran University of Medical Sciences
  • Mojgan Asgari
    • Department of Pathology, Oncopathology Research CentreIran University of Medical Sciences
    • Department of Pathology, Hasheminejad Kidney CenterIran University of Medical Sciences
  • Maryam Abolhasani
    • Department of Pathology, Oncopathology Research CentreIran University of Medical Sciences
    • Department of Pathology, Hasheminejad Kidney CenterIran University of Medical Sciences
  • Mehdi Shekarabi
    • Department of ImmunologyIran University of Medical Sciences
  • Jaleh Taeb
    • Department of Molecular MedicineIran University of Medical Sciences
  • Ahmad Shariftabrizi
    • Department of Pathology, Oncopathology Research CentreIran University of Medical Sciences
    • Department of Pathology, Danbury HospitalYale University
Original Article

DOI: 10.1007/s00262-013-1463-1

Cite this article as:
Mohsenzadegan, M., Madjd, Z., Asgari, M. et al. Cancer Immunol Immunother (2013) 62: 1609. doi:10.1007/s00262-013-1463-1

Abstract

New gene expressed in prostate (NGEP) is a newly diagnosed prostate-specific gene that is expressed only in normal prostate and prostate cancer cells. Discovery of tissue-specific markers may promote the development of novel targets for immunotherapy of prostate cancer. In the present study, the staining pattern and clinical significance of NGEP were evaluated in a series of prostate tissues composed of 123 prostate cancer, 19 high-grade prostatic intraepithelial neoplasia and 44 samples of benign prostate tissue included in tissue microarrays using immunohistochemistry. Our study demonstrated that NGEP localized mainly in the apical and lateral membranes and was also partially distributed in the cytoplasm of epithelial cells of normal prostate tissue. All of the examined prostate tissues expressed NGEP with a variety of intensities; the level of expression was significantly more in the benign prostate tissues compared to malignant prostate samples (P value <0.001). Among prostate adenocarcinoma samples, a significant and inverse correlation was observed between the intensity of NGEP expression and increased Gleason score (P = 0.007). Taken together, we found that NGEP protein is widely expressed in low-grade to high-grade prostate adenocarcinomas as well as benign prostate tissues, and the intensity of expression is inversely proportional to the level of malignancy. NGEP could be an attractive target for immune-based therapy of prostate cancer patients as an alternative to the conventional therapies particularly in indolent patients.

Keywords

NGEPProstate cancerImmunotherapyImmunohistochemistry

Abbreviations

Ano 7

Anoctamin 7

BPH

Benign prostatic hyperplasia

Epe

Extraprostatic extension

ESTs

Expressed sequence tags

FDA

Food and drug administration

HPIN

High-grade prostatic intraepithelial neoplasia

IHC

Immunohistochemistry

ISH

In situ hybridization

MAb

Monoclonal antibody

NGEP

New gene expressed in prostate

PBMC

Peripheral blood mononuclear cell

PCa

Prostate cancer

PSA

Prostate-specific antigen

PSMA

Prostate-specific membrane antigen

PSCA

Prostate stem cell antigen

TMA

Tissue macroarray

TRICOM

Triad of costimulatory molecules (B7.1, ICAM-1, LFA-3)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013